On the mode of action of thrombin-induced angiogenesis: thrombin peptide, TP508, mediates effects in endothelial cells via α_vβ₃ integrin

Summary

In a previous report we have presented evidence that thrombin interacts with α_vβ₃ integrin in endothelial cells at the molecular and cellular level. This interaction was shown to be of functional significance in vitro and in vivo and contributed to activation of angiogenesis by thrombin. In the present study, we have used a synthetic thrombin peptide, TP508, which represents residues 183 to 200 of human thrombin. This peptide lacks the catalytic site of thrombin but contains the thrombin RGD sequence. Immobilized (surface-coated) TP508 peptide, like thrombin, supported α_vβ₃ integrin-dependent endothelial cell attachment and haptotactic migration. These effects were specific (a scrambled TP508 peptide was without effect), and dosedependent. The RGD sequence was essential since a modified TP508 peptide, which contained RAD sequence instead of RGD, was inactive. Immobilized TP508 peptide stimulated phosphorylation of mitogen-activated protein kinases and focal adhesion kinase, the signal transduction pathways characteristic for integrin activation. On the other hand, TP508 peptide, when in solution, did not mimic other thrombin-promoted angiogenic effects, such as that of activation gelatinase A, upregulation of expression of vascular endothelial growth factor receptor mRNA or prostacyclin PGI₂ release in endothelial cells. On the contrary, soluble TP508 acted as an antagonist for the aforementioned effects of thrombin. TP508 peptide inhibited these thrombin-induced effects through a RGD and α. _vβ³-related mechanism. The antagonism with thrombin or thrombin receptor activating peptide was specific and involved at least in part mitogen-activated protein kinases activation. These results point to the importance of RGD sequence of thrombin in mediating effects on endothelial cells and angiogenesis.

Keywords

Thrombin,TP508 - α_vβ₃ integrin - RGD

• References

• 1 Macfarlane SR, Seatter MJ, Kanke T. et al. Proteinase-activated receptors. Pharmacol Rev 2001; 53: 245-82.
• 2 Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin and cancer. Chest 2003; 124: 58S-68S 2003;
• 3 Tsopanoglou NE, Pipili-Synetos E, Maragoudakis ME. Thrombin promotes angiogenesis by a mechanism independent of fibrin formation. Am J Physiol Cell Physiol 1993; 264: C1302-C1307.
• 4 Griffin CT, Srinivasan Y, Zheng YW. et al. A role for thrombin receptor signaling in endothelial cells during embryonic development. Science 2001; 293: 1666-70.
• 5 Tsopanoglou NE, Maragoudakis ME. On the mechanism of thrombin-induced angiogenesis. Potentiation of vascular endothelial growth factor activity on endothelial cells by up-regulation of its receptors. J Biol Chem 1999; 274: 23969-76.
• 6 Mohle R, Green D, Moore MA. et al. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997; 94: 663-9.
• 7 Huang YQ, Li JJ, Hu L. et al. Thrombin induces increased expression and secretion of VEGF in human FS4 fibroblasts, DU145 prostate cells and CHRF megakaryocytes. Thromb Haemost 2001; 86: 1094-8.
• 8 Huang YQ, Li JJ, Hu L. et al. Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothelial cells. Blood 2002; 99: 1646-50.
• 9 Tsopanoglou NE, Maragoudakis ME. On the mechanism of thrombin-induced angiogenesis: inhibition of attachment of endothelial cells on basement membrane proteins. Angiogenesis 1998; 01: 192-200.
• 10 Tsopanoglou NE, Andriopoulou P, Maragoudakis ME. On the mechanism of thrombin-induced angiogenesis: involvement of α_vβ₃ integrin. Am J Physiol Cell Physiol 2002; 283: C1501-C1510.
• 11 Zucker S, Conner C, DiMassmo BI. et al. Thrombin induces the activation of progelatinase A in vascular endothelial cells. J Biol Chem 1995; 270: 23730-8.
• 12 Brooks PC, Stromblad S, Sanders LC. et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin α_vβ₃ . Cell 1996; 85: 683-93.
• 13 Stiernberg J, Norfleet AM, Redin WR. et al. Acceleration of full-thickness would healing in normal rats by the synthetic thrombin peptide, TP508. Wound Rep Reg 2000; 08: 204-15.
• 14 Norfleet AM, Huang Y, Sower LE. et al. Thrombin peptide TP508 accelerates closure of dermal excisions in animal tissue with surgically induced ischemia. Wound Rep Reg 2000; 08: 517-29.
• 15 Dechantsreiter MA, Planker E, Matha B. et al. N-methylated cyclic RGD as highly active and selective alpha (V) beta 3 integrin antagonists. J Med Chem 1999; 42: 3033-40.
• 16 Hewett PW, Murray JC. Coexpression of flt-1, flt-4 and KDR in freshly isolated and cultured human endothelial cells. Bioch Biophys Res Commun 1996; 221: 697-702.
• 17 Maragoudakis ME, Kraniti N, Giannopoulou E. et al. Modulation of angiogenesis and progelatinase B by thrombin receptor mimetics and antagonists. Endothelium 2001; 08: 195-205.
• 18 Qi M, Ikematsu S, Maeda N. et al. Haptotactic migration induced by midkine. Involvement of protein-tyrosine phosphatase zeta. Mitogen-activated protein kinase and phosphotidylinositol 3-kinase. J Biol Chem 2001; 276: 15868-75.
• 19 Giancotti FG. Complexity and specificity of integrin signaling. Nat Cell Biol 2000; 02: E13-E14.
• 20 Eliceiri BP, Cheresh DA. The role of a. _v integrin during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999; 103: 1227-30.
• 21 Wheeler-Jones CPD, May MJ, Houliston RA. et al. Inhibition of MAP kinase (MEK) blocks endothelial PGI₂ release but has no effect on von Willebrand factor secretion or E-selectin expression. FEBS Let 1996; 388: 180-4.
• 22 Coughlin SR. Thrombin signaling and protease-activated receptors. Nature 2000; 407: 258-64.
• 23 Glenn KC, Frost GH, Bergmann S. et al. Synthetic peptides bind to high-affinity thrombin receptors and modulate thrombin mitogenesis. Peptide Res 1988; 01: 65-73.
• 24 Carney DH, Mann R, Redin WR. et al. Enhancement of incisional wound healing and neovascularization in normal rats by thrombin and synthetic thrombin receptor-activating peptides. J Clin Invest 1992; 89: 1469-77.
• 25 Sower LE, Payne DA, Meyers R. et al. Thrombin peptide, TP508, induces differential gene expression in fibroblasts a nonproteolytic activation pathway. Exp Cell Res 1999; 247: 422-31.
• 26 Abedi H, Zachary I. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J Biol Chem 1997; 272: 15442-51.
• 27 Bar-Shavit R, Eldor B, Vlodavsky I. Binding of thrombin to subendothelial extracellular matrix: protection and expession of functional properties. J Clin Invest 1989; 84: 1096-104.
• 28 Wilner GD, Danitz MP, Mudd SM. et al. Selective immobilization of alpha-thrombin by surface-bound fibrin. J Lab Clin Med 1981; 97: 403-11.
• 29 Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001; 21: 1104-17.
• 30 Thompson WD, Smith E, Stirk CM. et al. Angiogenic activity of fibrin degratation products is located in fibrin fragment E. J Pathol 1992; 168: 47-53.
• 31 Bootle-Wilbraham CA, Tazzyman S, Marshall JM. et al. Fibrinogen E-fragment inhibits the migration and tubule formation of human dermal microvascular endothelial cells in vitro. Cancer Res 2000; 60: 4719-24.
• 32 Bar-Shavit R, Eskohjido Y, Fenton II JW. et al. Thrombin adhesive properties: induction by plasmin and heparan sulfate. J Cell Biol 1993; 123: 1279-87.
• 33 Stetler-Stevenson WG. Dynamics of matrix turnover during pathological remodeling of the extracellular matrix. Am J Pathol 1996; 48: 1345-50.
• 34 Seiffert D, Smith JW. The cell adhesion domain in plasma vitronectin is cryptic. J Biol Chem 1997; 272: 13705-10.
• 35 Languino RL, Plescia J, Duperray A. et al. Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway. Cell 1993; 73: 1423-34.
• 36 Sajid M, Zhao R, Pathak A. et al. α_vβ₃ integrin antagonists inhibits thrombin-induced proliferation and focal adhesion formation in smooth muscle cells. Am J Physiol Cell Physiol 2003; 285: C1330-C1338.
• 37 Even-Ram SC, Maoz M, Pokroy E. et al. Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the α_vβ₅ integrin. J Biol Chem 2001; 276: 10950-62.
• 38 Maeshima Y, Colorado PC, Kalluri R. Two RGD-independent α_vβ₃ integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem 2000; 275: 23745-50.
• 39 Rehn M, Veikkola T, Kukk-Valdre E. et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci 2001; 98: 1024-9.